Yazar "Binbay, Murat" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Dose-Dependent Protective Effect of Ivabradine against Ischemia-Reperfusion-Induced Renal Injury in Rats
    (Karger, 2012) Beytur, Ali; Binbay, Murat; Sarihan, M. Ediz; Parlakpinar, Hakan; Polat, Alaadin; Gunaydin, M. Orhun; Acet, Ahmet
    Background/Aims: This study was designed to investigate the dose-dependent protective effect of ivabradine, a specific inhibitor of the cardiac sinoatrial node, on renal ischemia-reperfusion (I/R) injury in rats. Methods: Rats were divided into six groups: group 1, control; group 2, I/R (60 min ischemia followed by 24 h reperfusion); groups 3 and 4, 0.6-6 mg/kg ivabradine; and groups 5 and 6, sham+0.6-6 mg/kg ivabradine. At the end of the study, malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase contents were assayed in the kidney tissues; serum blood levels of urea nitrogen (BUN), creatinine (Cr) and albumin also were determined. Results: Tissue MDA levels were found to be significantly higher in the I/R group, whereas SOD and CAT levels were lower when compared to the control group. Ivabradine (0.6 mg/kg) treatment reduced the MDA levels and elevated the SOD and CAT enzyme activity. Treatment with a dose of 6 mg/kg ivabradine further increased MDA levels and did not ameliorate SOD or CAT activities. Serum levels of BUN and Cr were significantly higher in the I/R group. I/R+0.6 mg ivabradine reduced the elevated BUN and Cr levels. Conclusion:This study indicates that ivabradine exerts a dose-dependent response beyond heart rate reduction against renal I/R injury. Copyright (C) 2011 S. Karger AG, Basel
  • Küçük Resim Yok
    Öğe
    Effect of Simple Malrotation on Percutaneous Nephrolithotomy: A Matched Pair Multicenter Analysis
    (Elsevier Science Inc, 2011) Binbay, Murat; Istanbulluoglu, Okan; Sofikerim, Mustafa; Beytur, Ali; Skolarikos, Andreas; Akman, Tolga; Huri, Emre
    Purpose: In this multicenter study we compared the outcome of percutaneous nephrolithotomy in patients with and without malrotated kidneys. Materials and Methods: A total of 44 patients (group 1) at 6 institutions who underwent percutaneous nephrolithotomy for kidneys with simple malrotation were enrolled in our study. Attending physicians in our group also provided the same number of cases of percutaneous nephrolithotomy done for nonmalrotated (normal) kidneys (group 2). Group 2 patients were selected by match pairing. Operative and postoperative data on the 2 groups were compared using the chi-square, Student t and Fisher exact tests. Results: As a result of match pairing, the 2 groups were similar in age, gender, body mass index, and stone size and site. Mean +/- SD stone size was 5.9 +/- 3.5 cm(2) in group 1. Multiple access attempts were required in 9 (20.5%) and 7 cases (15.9%) in groups 1 and 2, respectively (p > 0.05). Mean fluoroscopy time was 7.0 +/- 3.9 minutes in the malrotated kidney group and 7.3 +/- 4.5 minutes in the nonmalrotated kidney group (p > 0.05). The mean hemoglobin decrease after percutaneous nephrolithotomy was significantly higher in group 1 (-1.9 vs -1.3 gm/dl, p = 0.008) but the blood transfusion rate was similar in the 2 groups. The procedure success rate in groups 1 and 2 was 77.3% and 79.5%, respectively (p > 0.05). Conclusions: Percutaneous nephrolithotomy is safe and effective even in patients with larger kidney stones and malrotated kidneys.